Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB

H.C. Wainwright analyst Sara Nik has reiterated their bullish stance on 7V3 stock, giving a Buy rating on January 15.

Sara Nik has given his Buy rating due to a combination of factors tied to Cantargia AB’s lead asset, nadunolimab, and its expanding clinical footprint. The initiation of the investigator‑sponsored Phase 1b/2 trial in chemotherapy‑refractory MSS colorectal cancer offers a cost‑efficient way to probe a new, difficult‑to‑treat patient population, while further reinforcing the drug’s mechanism of action. Nik views this study as strategically complementary to the prior encouraging results seen in pancreatic and non‑small cell lung cancer, suggesting broader potential for nadunolimab across solid tumors.

In her view, early safety and biomarker data from the MSS‑CRC program could serve as important de‑risking events ahead of the planned pivotal pancreatic cancer trial expected around mid‑2026, which remains the central value driver. If nadunolimab can effectively remodel the tumor microenvironment so that PD‑1 inhibitors become active in historically unresponsive MSS‑CRC, the commercial opportunity could extend meaningfully beyond the current core indications. Coupled with the low incremental cost of the new study, the diversified “shots on goal” across oncology indications and the potential to materially enlarge the addressable market underpin her Buy rating and SEK14 price target.

Nik covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Cantargia AB, and Cidara Therapeutics. According to TipRanks, Nik has an average return of 43.6% and a 36.36% success rate on recommended stocks.

In another report released on January 15, TipRanks – DeepSeek also initiated coverage with a Buy rating on the stock with a SEK7.00 price target.